AVO:LSE-Advanced Oncotherapy plc (GBX)

COMMON STOCK | Medical Devices | LSE

Last Closing Price

GBX 36.00

Change

-0.25 (-0.69)%

Market Cap

GBX 0.17B

Volume

0.03M

Avg Analyst Target

N/A

Avg User Target

GBX
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


Advanced Oncotherapy plc (AVO) Stock Analysis:
Based on the Advanced Oncotherapy plc stock forecasts from 0 analysts, the average analyst target price for Advanced Oncotherapy plc is not available over the next 12 months. Advanced Oncotherapy plc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Advanced Oncotherapy plc is Very Bearish, which is based on 0 positive signals and 4 negative signals. At the last closing, Advanced Oncotherapy plc’s stock price was GBX 36.00. Advanced Oncotherapy plc’s stock price has changed by -1.00 % over the past week, -0.67 % over the past month and +5.88 % over the last year.

About

Advanced Oncotherapy plc, together with its subsidiaries, engages in designing, assembling, selling, and maintaining proton-based radiotherapy systems for treatment of cancer. It is developing Linac Image Guided Hadron Technology, a proton therapy system for treating cancer. The ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-12-02 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SN:LSE Smith & Nephew plc

N/A

GBX10.90B 26.21 10.62
EKF:LSE EKF Diagnostics Holdings plc

+0.50 (+0.67%)

GBX0.34B 21.43 12.79
CREO:LSE Creo Medical Limited

-0.60 (-0.44%)

GBX0.26B N/A N/A
MGP:LSE Medica Group Plc

+4.00 (+2.48%)

GBX0.19B 80.50 27.01
CIR:LSE Circassia Group Plc

-0.95 (-2.50%)

GBX0.16B N/A N/A
POLX:LSE Polarean Imaging plc

N/A

GBX0.12B N/A N/A
IDH:LSE Immunodiagnostic Systems Holdi..

N/A

GBX0.11B 290.77 22.62
BELL:LSE Belluscura Plc

N/A

GBX0.11B N/A N/A
IHC:LSE Inspiration Healthcare Group p..

N/A

GBX0.08B 17.58 11.56
KMK:LSE Kromek Group plc

-0.23 (-1.72%)

GBX0.06B N/A 19.23

ETFs Containing AVO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 5.88% 42% F 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.88% 42% F 41% F
Trailing 5 Years  
Capital Gain -38.46% 56% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -38.46% 56% F 15% F
Average Annual (5 Year Horizon)  
Capital Gain 17.89% 75% C 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.89% 75% C 72% C-
Risk Return Profile  
Volatility (Standard Deviation) 67.19% 17% F 23% F
Risk Adjusted Return 26.63% 67% D+ 45% F
Market Capitalization 0.17B 71% C- 40% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 4.66 21% F 19% F
Price / Cash Flow Ratio -8.19 57% F 80% B-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -60.26% 14% F 6% F
Return on Invested Capital -34.00% 21% F 10% F
Return on Assets -10.98% 36% F 10% F
Debt to Equity Ratio 18.71% 56% F 60% D-
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.96 29% F 58% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector